Back to Authors

Vinters, Harry V.

https://orcid.org/0000-0002-2965-1240

A5040650353 | I161318765

Mayo Clinic

University of California, Los Angeles

Citations 15

Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease

JAMA Neurology | September 8, 2014 | Volume: 71 | Issue: 11 | Pages: 1394

10.1001/jamaneurol.2014.1491 | PMID 25199842

O4‐07‐03: PATHOLOGIC VALIDATION OF THE EADC‐ADNI HARMONIZED HIPPOCAMPAL PROTOCOL

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2014.04.423

IC‐P‐184: PATHOLOGIC VALIDATION OF THE EADC‐ADNI HARMONIZED HIPPOCAMPAL PROTOCOL

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2014.05.191

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Alzheimer's & Dementia | January 19, 2012 | Volume: 8 | Issue: 1 | Pages: 1-13

10.1016/j.jalz.2011.10.007 | PMID 22265587

Abstract A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards

Stroke | August 17, 2006 | Volume: 37 | Issue: 9 | Pages: 2220-2241

10.1161/01.str.0000237236.88823.47 | PMID 16917086

Background and Purpose— One in 3 individuals will experience a stroke, dementia or both. Moreover, twice as many individuals will have cognitive impairment short of dementia as either stroke or dementia. The commonly used stroke scales do not measure cognition, while dementia criteria focus on the late stages of cognitive impairment, and are heavily biased toward the diagnosis of Alzheimer disease. No commonly agreed standards exist for identifying and describing individuals with cognitive impairment, particularly in the early stages, and especially with cognitive impairment related to vascular factors, or vascular cognitive impairment. Methods— The National Institute for Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network (CSN) convened researchers in clinical diagnosis, epidemiology, neuropsychology, brain imaging, neuropathology, experimental models, biomarkers, genetics, and clinical trials to recommend minimum, common, clinical and research standards for the description and study of vascular cognitive impairment. Results— The results of these discussions are reported herein. Conclusions— The development of common standards represents a first step in a process of use, validation and refinement. Using the same standards will help identify individuals in the early stages of cognitive impairment, will make studies comparable, and by integrating knowledge, will accelerate the pace of progress.